Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IODINE-123-IODOBENZAMIDE SPECT ASSESSMENT OF DOPAMINE D-2 RECEPTOR OCCUPANCY IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS
Autore:
DRESEL S; TATSCH K; DAHNE I; MAGER T; SCHERER J; HAHN K;
Indirizzi:
UNIV MUNICH,DEPT NUCL MED,MARCHIONINISTR 15 D-81377 MUNICH GERMANY UNIV MUNICH,DEPT NUCL MED D-81377 MUNICH GERMANY UNIV MUNICH,DEPT PSYCHIAT D-81377 MUNICH GERMANY STATE MENTAL HOSP HAAR GERMANY
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 7, volume: 39, anno: 1998,
pagine: 1138 - 1142
SICI:
0161-5505(1998)39:7<1138:ISAODD>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHOTON-EMISSION TOMOGRAPHY; ANTIPSYCHOTIC-DRUGS; IN-VIVO; ATYPICAL NEUROLEPTICS; INVITRO BINDING; HUMAN BRAIN; CLOZAPINE; BLOCKADE; IBZM; CLONING;
Keywords:
IODINE-123-IODOBENZAMIDE SPECT; SCHIZOPHRENIA PATIENTS; RISPERIDONE; EXTRAPYRAMIDAL SYMPTOMS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
S. Dresel et al., "IODINE-123-IODOBENZAMIDE SPECT ASSESSMENT OF DOPAMINE D-2 RECEPTOR OCCUPANCY IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS", The Journal of nuclear medicine, 39(7), 1998, pp. 1138-1142

Abstract

The recently introduced neuroleptic, risperidone, was expected to block fewer dopamine D-2 receptors than typical neuroleptics (e.g., haloperidol), but at comparable potency, The aim of this study was to evaluate the degree of dopamine D-2 receptor occupancy in relation to the neuroleptic dosage and to correlate the findings with the presence of extrapyramidal symptoms (EPS), Additionally the data were compared to previous iodobenzamide (IBZM) SPECT findings in patients treated with other neuroleptics, haloperidol and clozapine, Methods: In 20 patients with schizophrenia [Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised)] treated with mean daily doses of risperidone ranging from 0.029 to 0.128 mg/kg body weight, SPECT was performed2 hr after intravenous injection of 185 MBq I-123-IBZM, a selective dopamine D-2 receptor ligand, Striatal IBZM binding was assessed by calculating a striatal/frontal cortex ratio, expressed as a percentage ofthe control value. Results: Selective dopamine D-2 receptor binding of the ligand was reduced in all treated patients, with binding values ranging from 7% to 68%. The degree of occupancy displayed an exponential dose-response relationship (r = -0.86; p < 0.0001). The slope of the curve was between those of haloperidol and clozapine but was closer and more similar in shape to the curve of haloperidol. Extrapyramidal symptoms were observed in 8 of 20 patients with binding values between7% and 47%. However, there was no clear relationship between the degree of receptor occupancy and the presence of EPS, Conclusion: The findings suggest an exponential dose-response relationship between the daily dosage of risperidone and the dopamine D-2 receptor occupancy. The blockade of specific striatal IBZM binding found under therapy with risperidone is between those of haloperidol and clozapine. The dose-response curve for risperidone, however, shows greater similarity to that of haloperidol.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:53:06